Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine–Cisplatin Substantially Improves Survival for Liver‑Confined Unresectable Intrahepatic Cholangiocarcinoma: PUMP‑2 Trial Results
The PUMP‑2 phase II trial reports that hepatic arterial infusion (HAIP) of floxuridine combined with systemic gemcitabine–cisplatin achieved a 1‑year overall survival of 80% and median OS of 22.3 months in unresectable liver‑confined intrahepatic cholangiocarcinoma, surpassing historical gem‑cis cohorts.